Technology, Healthcare Jan 18, 2022 10:59 AM (GMT+8) · EqualOcean
Zhang Junhao, chief analyst of the trade and retail industry of Guosen Securities, said that it is difficult for the medical and American sector in 2022 to have the trend of general rise in the first half of 2021. When the whole industry is more and more fully aware, it must be the preferred high-quality target. Among them, relatively speaking, the listed companies of medical devices in the upstream will have more growth toughness, and the downstream sectors, such as medical institution companies, may be disturbed by supervision in the short term. Compliance leading companies will slowly recover from the high pressure of supervision. The whole year's market of the plate is still worth looking forward to. In the process, it must be the leading companies and enterprises with performance support.

This text is a result of machine translation.